Compile Data Set for Download or QSAR
Report error Found 241 Enz. Inhib. hit(s) with all data for entry = 11327
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607988(US11691963, Example I-147)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607987(US11691963, Example I-146)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607986(US11691963, Example I-145)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607993(US11691963, Example I-151)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607992(US11691963, Example I-150)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607991(US11691963, Example I-149)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607997(US11691963, Example I-155)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607996(US11691963, Example I-154)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607995(US11691963, Example I-153)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607994(US11691963, Example I-152)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608001(US11691963, Example I-159)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608000(US11691963, Example I-158)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607999(US11691963, Example I-157)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607998(US11691963, Example I-156)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607973(US11691963, Example I-133)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607972(US11691963, Example I-132)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607971(US11691963, Example I-131)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607970(US11691963, Example I-130)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607977(US11691963, Example I-136)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607975(US11691963, Example I-135-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607974(US11691963, Example I-134)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607981(US11691963, Example I-140)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607980(US11691963, Example I-139)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607979(US11691963, Example I-138)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607978(US11691963, Example I-137)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607983(US11691963, Example I-142)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607982(US11691963, Example I-141)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608020(US11691963, Example I-175-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608025(US11691963, Example I-178)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608024(US11691963, Example I-177)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608023(US11691963, Example I-176-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608022(US11691963, Example I-176-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608029(US11691963, Example I-182)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608028(US11691963, Example I-181)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608026(US11691963, Example I-179)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608033(US11691963, Example I-186)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608032(US11691963, Example I-185)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608031(US11691963, Example I-184)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608030(US11691963, Example I-183)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608004(US11691963, Example I-162-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608003(US11691963, Example I-161)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608002(US11691963, Example I-160)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608009(US11691963, Example I-165)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608008(US11691963, Example I-164)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608007(US11691963, Example I-163-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608006(US11691963, Example I-163-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608012(US11691963, Example I-168)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608011(US11691963, Example I-167 | US11691963, Example I-...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608010(US11691963, Example I-166)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608016(US11691963, Example I-172-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 241 total ) | Next | Last >>
Jump to: